TipRanks (Wed, 17-Dec 6:25 AM ET)
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
TipRanks (Tue, 16-Dec 11:45 AM ET)
Market Chameleon (Tue, 16-Dec 5:29 AM ET)
Aldeyra drops as FDA delays review of marketing application for lead drug
Seeking Alpha News (Tue, 16-Dec 7:34 AM ET)
Aldeyra Therapeutics Faces FDA PDUFA Date Extension
TipRanks (Tue, 16-Dec 6:32 AM ET)
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga (Tue, 16-Dec 5:53 AM ET)
Business Wire (Mon, 15-Dec 7:30 PM ET)
Aldeyra Therapeutics Completes Promising Phase 2 Trial for Alcohol-Associated Hepatitis
TipRanks (Sun, 14-Dec 11:35 AM ET)
Business Wire (Thu, 13-Nov 7:00 AM ET)
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Business Wire (Tue, 11-Nov 7:01 AM ET)
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Aldeyra Therapeutics trades on the NASDAQ stock market under the symbol ALDX.
As of December 19, 2025, ALDX stock price declined to $4.99 with 488,525 million shares trading.
ALDX has a beta of 4.91, meaning it tends to be more sensitive to market movements. ALDX has a correlation of 0.34 to the broad based SPY ETF.
ALDX has a market cap of $300.21 million. This is considered a Small Cap stock.
Last quarter Aldeyra Therapeutics reported $0 in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-24 million and exceeded earnings estimates by $.04.
In the last 3 years, ALDX traded as high as $11.97 and as low as $1.14.
The top ETF exchange traded funds that ALDX belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ALDX has underperformed the market in the last year with a return of +2.3%, while the SPY ETF gained +17.3%. In the last 3 month period, ALDX fell short of the market, returning -0.4%, while SPY returned +3.3%. However, in the most recent 2 weeks ALDX has outperformed the stock market by returning +2.3%, while SPY returned -0.5%.
ALDX support price is $4.73 and resistance is $5.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALDX shares will trade within this expected range on the day.
